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Abstract
Epigenetics are thought to play a major role in the carcinogenesis of multiple sporadic colorectal cancers (CRC). Previous
studies have suggested concordant DNA hypermethylation between tumor pairs. However, only a few methylation markers
have been analyzed. This study was aimed at describing the epigenetic signature of multiple CRC using a genome-scale
DNA methylation profiling. We analyzed 12 patients with synchronous CRC and 29 age-, sex-, and tumor location-paired
patients with solitary tumors from the EPICOLON II cohort. DNA methylation profiling was performed using the Illumina
Infinium HM27 DNA methylation assay. The most significant results were validated by Methylight. Tumors samples were also
analyzed for the CpG Island Methylator Phenotype (CIMP); KRAS and BRAF mutations and mismatch repair deficiency status.
Functional annotation clustering was performed. We identified 102 CpG sites that showed significant DNA
hypermethylation in multiple tumors with respect to the solitary counterparts (difference in b value $0.1). Methylight
assays validated the results for 4 selected genes (p = 0.0002). Eight out of 12(66.6%) multiple tumors were classified as CIMP-
high, as compared to 5 out of 29(17.2%) solitary tumors (p = 0.004). Interestingly, 76 out of the 102 (74.5%) hypermethylated
CpG sites found in multiple tumors were also seen in CIMP-high tumors. Functional analysis of hypermethylated genes
found in multiple tumors showed enrichment of genes involved in different tumorigenic functions. In conclusion, multiple
CRC are associated with a distinct methylation phenotype, with a close association between tumor multiplicity and CIMP-
high. Our results may be important to unravel the underlying mechanism of tumor multiplicity.
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Introduction
Up to 10% of all colorectal cancer (CRC) patients develop more
than one tumor in the colorectum, either synchronously
(diagnosed at the same time) or metachronously (diagnosed during
follow-up) [1,2,3]. Tumor multiplicity is thought to occur because
of a common etiologic factor (genetic or environmental) and
provide a good model to examine common molecular alterations
and, more specifically, a potential field effect [4,5,6,7]. Genetics
explain only a part of the spectrum of multiple CRCs, especially
those occurring in the context of Lynch syndrome (caused by
mutations in the mismatch repair genes) [8,9,10], familial
associated polyposis (FAP) [11], MUTYH associated polyposis
(MAP) [11] and other forms of colorectal polyposis [12]. On the
other side, the concept of field defect has been proposed to explain
tumor multiplicity through a generalized cellular or molecular
disorder in the entire colorectal mucosa, causing a putative field
effect (so called ‘‘field cancerization’’) [6,7], such as in serrated
polyposis syndrome [13,14,15]. However, the definitive underlying
pathogenic mechanism of tumor multiplicity remains elusive.
In the non-hereditary scenario, previous studies have found
common molecular alteration patterns between CRC pairs and in
the normal colonic mucosa of patients with multiples colorectal
tumors, supporting a putative field defect [4,10,14,16]. In contrast
to genetic alterations, which are not commonly found in normal
mucosa from cancer patients, epigenetics are thought to play a
major role in the carcinogenesis of those individuals that develop
multiple tumors [4,5,14,17,18,19,20,21]. In this sense, it has been
suggested that synchronous CRCs are more frequently associated
with the CpG island methylator phenotype (CIMP) [4], BRAF
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Table 1. Clinical and tumor characteristics of solitary and multiple colorectal cancer patients.
Clinico-pathological features Solitary CRC patients (n = 29) Multiple CRC patients (n = 12) p value
Age (years) 71.169.1 74.067.1 0.33
Age
,65years 6(20%) 1(8.3%) 0.65
$65years 23(79%) 11(91.7%)
Gender
Male 20(69%) 9(75%) 1
Female 9(31%) 3(25%)
Body mass index (Kg/m2)
,30 23(82%) 9(75%) 0.67
$30 5(18%) 3(25%)
Tumor location1
Proximal 6 (20.6%) 2 (16.6%) 0.57
Distal 23 (79.4%) 10 (38.4%)
Family history of CRC in any first degree relative
No 26(89.6%) 8(66.7%) 0.91
Yes 3(10.3%) 4(33.3%)
Family history of Lynch-related tumor* in any first degree
relative
No 22(75.9%) 8(66.7%) 0.39
Yes 7(24.1%) 4(33.3%)
Microsatellite instability status
Stable 25(86.2%) 12(100%) 0.4
Unstable 2(6.9%) 0(0%)
Tumor differentiation
Well or moderate 24(100%)2 11(100%)3 1
Poor - -
Mucinous tumor
No 20(83.3%)2 7(70%)4 0.394
Yes 4(16.7%) 3(30%)
TNM stage
I 4(13.8%) 2(16.7%) 0.298
II 9(31%) 6(50%)
III 11(37.9%) 1(8.3%)
IV 5(17.2%) 3(25%)
Somatic BRAF mutational status
Wild type 24 (100%)2 9 (100%)5 1
Mutated - -
Somatic KRAS mutational status
Wild type 14(58.3%)2 6(66.7%)5 1
Mutated 10(41.7%) 3(33.3%)
CIMP-high status6
Positive 5(17.2%) 8(66.7%) 0.004
Negative 24(82.8%) 4(33.3%)
* Lynch-related tumors: colorectal, endometrial, ovary, stomach, urinary tract, biliary, pancreas, brain.
1Referred to the splenic flexure;
2Referred to 24 patients;
3Referred to 11 patients;
4referred to 10 patients;
5referred to 9 patients.
6Based on Illumina Infinium DNA methylation assay.
CRC, colorectal cancer.
doi:10.1371/journal.pone.0091033.t001
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mutation and microsatellite instability [10]. Indeed, our group
compared a set of 41 pair-wise multiple and solitary CRCs and
identified hypermethylation of the MGMT2 locus and RASSF1A
gene as variables independently associated with tumor multiplicity.
Moreover, several studies have found concordant methylation
patterns in tumor pairs [4,14,17,18]. On the other hand, global
DNA hypomethylation has been linked to genomic instability and
carcinogenesis [22,23] and, recently, higher hypomethylation of
LINE-1 (a surrogate marker of global DNA methylation) in
normal colonic mucosa has been found to be a distinctive feature
of patients with synchronous CRCs [14]. All these results suggest
that shared environmental and/or genetic background may cause
concordant patterns of DNA methylation in patients with multiple
tumors. However, only a few methylation markers have been
analyzed and high throughput techniques with genome wide
capability are needed to find and better understand the underlying
epigenetic signature of multiple sporadic CRCs.
In this study we aimed at describing the underlying epigenetic
signature that differentiates multiple from solitary CRC tumors
using a genome-wide approach. For this purpose, we analyzed 12
synchronous and 29 control solitary CRCs derived from the
population-based EPICOLON-II cohort, and evaluated the
genome-scale methylation profile using the Illumina Infinium
HM27 DNA methylation assay, an approach that has not been
previously attempted.
Materials and Methods
Patients and samples
Twelve patients with synchronous CRC and 29 age-, sex-, and
tumor location-paired patients with solitary tumors were recruited
from the EPICOLON II cohort, a multicenter population-based
study performed in Spain between 2006 and 2007 [24].
Synchronous tumors were clearly separated by normal colonic
mucosa and both were invasive (at least pT1). Patients were
followed until death or March 2012, whichever came first.
Demographic, clinical and tumor-related characteristics of patients
included in the study are summarized in Table 1. Exclusion
criteria for the present study were colorectal polyposis syndromes,
Lynch syndrome, and personal history of inflammatory bowel
disease. The Institutional Ethics Committee of each participating
hospital (see Acknowledgements) approved the study, and written
informed consent was obtained from all patients.
Frozen tumor colorectal tissues were obtained at surgery from
all patients, and immediately stored at 280u until use. In patients
with multiple lesions, tissue sample was obtained from one of the
tumors (the most advanced or the largest one when multiple
tumors had the same tumor stage).
DNA extraction and bisulfite conversion
Frozen samples were thawed and genomic DNA was isolated
using QIAamp DNA Mini Kit (Qiagen, Valencia, CA) according
to the manufacturer’s instructions. Bisulfite treatment was carried
out on genomic DNA using the EZ DNA Methylation-Gold Kit
(Zymo Research, Orange, CA) according to the manufacturer’s
protocol.
Infinium array
We performed DNA methylation profiling from 12 synchronous
and 29 solitary CRCs using Infinium methylation assay with
HumanMethylation27 BeadChip (Illumina, San Diego, CA),
which is capable of simultaneously analyze the methylation status
of 27,578 individual CpG sites covering 14,495 protein-coding
genes and 110 miRNAs [25,26,27]. Whole genome amplification,
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labeling, hybridization and scanning were performed according to
the manufacturer’s instruction at a core facility (Centre de
Regulacio´ Geno`mica, Barcelona, Catalonia, Spain). Methylation
status was measured as the ratio of signal from a methylated probe
relative to both methylated and unmethylated probe signals.
Methylation ratios were extracted using the Methylation Module
in the Illumina Bead Studio following average normalization.
Quantitative b-value ranges from 0 (0% methylation) to 1 (100%
methylation). The p-value cut off for detected probes (different
from background measurements) was set at 0.05. We excluded
probes that were previously published to be unreliable (those
containing single-nucleotide polymorphisms (SNPs) and those
repetitive sequences that covered the targeted CpG dinucleotide)
and those that were designed for sequences on either the X or the
Y chromosome. Together, we masked data points for 7549 probes
[27]. Complete microarray dataset is available at GEO (Gene
Expression Omnibus; accession number GSE52573).
Definition of CIMP-high tumors based on the Infinium
assay
We classified tumors as CIMP-high (CIMP-H), CIMP-low
(CIMP-L) and CIMP-0 based on a 2-step panels of markers
recently described by Hinoue et al based on the Illumina Infinium
HM27 DNA methylation assay [27]. The first panel (B3GAT2,
FOXL2, KCNK13, RAB31, and SLIT1) qualifies a sample as CIMP
(High and Low) versus CIMP-0 if b-value is $0.1 in three or more
markers. The second marker panel (FAM78A, FSTL1, KCNC1,
MYODCD and SLC6A4) distinguishes CIMP-H versus CIMP-L
tumors if b-value is $0.1 in three or more markers (Table 2).
These markers have shown to display 100% sensitivity and 100%
specificity to identify CIMP-H tumors [27].
Technical validation of the Infinium assay using
Methylight
Methylight technique for quantitative analysis of methylation
was used for the technical validation of the results observed in the
Illumina Infinium assay [28]. The following strict criteria were
used to selected candidate genes for validation: 1) solitary tumor
had a b value ,0.2; and 2) multiple tumors had either a b value
.0.3 and a difference in b value $0.2; and 3) adjusted p value
,0.05; and 4) previous evidence of tumor suppressive features
based on the published literature. Following these criteria, we
selected 4 genes for technical validation (MAP1B, HTRA1,
ALOX15, TIMP3). Locus specific PCR primers and probes are
listed on Table S1 and were specifically designed for bisulfited-
converted DNA sequences and located at each gene promoter
region. Methylight was carried out as previously described, using
ALUC4 as internal control [17,28].
Evaluation of tumor mismatch repair deficiency
Tumor mismatch repair deficiency was evaluated by both
microsatellite instability (MSI) testing and immunostaining
including evaluation of MSH2, MLH1, MSH6 and PMS2 as
previously described [29]. MSI status was assessed using BAT26
and NR24 quasimonomorphic markers as previously described
[30]. Tumors were classified as MSI when either of the two
markers was unstable.
Evaluation of BRAF and KRAS mutation status
BRAF mutations at codon 600 in exon 15, and KRAS mutations
at codons 12 and 13 in exon 2 were analyzed by Methylight and
direct sequencing, respectively, as previously published [31].
Functional annotation clustering of differentially
methylated genes between multiple and solitary
colorectal cancers
We used The Database for Annotation, Visualization and
Integrated Discovery (DAVID) [32] to identify pathways relevant
to carcinogenesis based on the genes that showed significantly
differential methylation between multiple and solitary multiple
tumors (difference in b value $0.1 and p,0.05) (DAVID: http://
david.abcc.ncifcrf.gov).
Statistical analysis
Logistic regression adjusted for age, sex and tumor location was
used to evaluate the difference in DNA methylation b-values for
each probe between two independent groups. The Illumina
Infinium DNA methylation b-values were represented graphically
using a heatmap, generated by the R/Bioconductor packages.
Clinicopathological features were compared using Chi-square
(qualitative variables) and t-tests (quantitative variables). Methy-
light quantitative data (percentage methylation ratio, PMR) was
analyzed using the Mann-Whitney U test. A p-value,0.05 was
considered statistically significant. Statistical analysis and data
visualization were carried out using the R/Bioconductor software
package and SSPS software (v.15).
Results
Differential methylation between multiple and solitary
tumors
Twelve patients with multiple CRC and 29 age-, sex-, and
tumor location-paired patients with solitary tumors constituted the
basis of this study. Demographic and tumor characteristics from
patients included in this study are listed in Table 1. We used
Illumina Infinium HM27 DNA methylation assay, which assesses
the DNA methylation status of 27,578 CpG sites located at the
promoter regions of over 14,000 protein-coding genes. We
identified 102 CpG sites that showed significant DNA hyper-
methylation in multiple tumors with respect to solitary ones
(difference in b value $0.1 and p,0.05). Using more stringent
criteria (difference in b value$0,2; p,0.05), we identified 36 CpG
sites significantly hypermethylated (see detailed list of genes in
Table S2). A heatmap showing the most significantly hyper-
methylated CpG sites that differentiate multiple and solitary
tumors is shown in Figure 1. Overall, these results show that
multiple tumors are associated with a distinct methylation
phenotype, irrespective of age, sex and tumor location.
Technical validation of microarray results
In order to technically validate the results of Infinium assay we
used stringent criteria to select probes that were significantly
hypermethylated in multiple tumors compared to solitary lesions
(b value in solitary tumors ,0.2; b value .0.3 in multiple tumors;
difference in b value between multiple and solitary tumors $0.2;
and an adjusted p value,0.05). In order to select biologically
relevant CpG sites, we prioritized genes with previous evidence of
tumor suppressor features. Following these criteria, we selected
MAP1B, HTRA1, ALOX15, and TIMP3 for validation in five
paired multiple and solitary tumors. Results are shown in
Figure 2. Globally, we found a significantly higher methylation
levels in multiple tumors compared to solitary ones (overall PMR,
14% versus 2.7%, respectively; p = 0.0002). As shown in Figure 2,
all four markers showed higher levels of methylation in multiple
tumors with respect to the solitary ones, thus reinforcing the
consistency of our results.
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CIMP-high is associated with tumor multiplicity
We next analyzed the CIMP status of multiple and solitary
tumors based on the recently developed gene marker panels
defined by Hinoue et al [27]. This panel has recently shown to
outperform the Methylight-based five-marker panel described by
Weisenberger [33]. Ten out of the 12 (83%) multiple tumors and
25 out of the 29 (86.2%) solitary CRC showed hypermethylation
of three or more markers from the first panel (i.e. B3GAT2,
FOXL2, KCNK13, RAB31, and SLIT1), so they were classified as
CIMP tumors. Based on the second panel (i.e. FAM78A, FSTL1,
KCNC1, MYOCD, and SLC6A4), 8 out of the 12 (66.6%) multiple
tumors were finally classified as CIMP-H, as compared to 5 out of
the 29 (17.2%) solitary tumors (p = 0.004) (Table 2). CIMP-H
tumors displayed significant hypermethylation (difference in b
value $0.1; p value,0.05) in 301 CpG sites (109 with a difference
in b value $0.2; p value,0.05). A heatmap showing the most
significant CpG sites that differentiate CIMP-H and CIMP-L/0
tumors is shown in Figure 3. A detailed list with CIMP-H
hypermethylated CpG sites is shown in Table S3. Interestingly,
76 out of the 102 hypermethylated CpG sites in multiple tumors
were also seen to be hypermethylated in CIMP-H tumors
(Figure 4). There were no BRAF mutations in any tumor. Our
results show a close association between tumor multiplicity and
CIMP, irrespective of age, sex and tumor location. This
Figure 1. Heatmap showing the 90 most significantly hypermethylated CpG sites that differentiate multiple CRCs (n = 12) with
respect to solitary tumors (n = 29) based on the Infinium DNA methylation data. The DNA methylation b-values are represented by using a
color scale from red (high DNA methylation) to green (low DNA methylation). Rows represent probes and columns represent tumor samples. Clinical
and molecular features (group, gender, tumor location, CIMP-H and KRASmutational status) are represented above the heatmap with horizontal bars.
doi:10.1371/journal.pone.0091033.g001
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observation is in agreement with a previous larger study in which
tumors were classified using Methylight-based markers [4], thus
reinforcing the field-defect theory.
Association between KRAS mutations and
hypermethylation
KRAS mutations have been associated to a methylation
phenotype called CIMP-low, in which hypermethylation of a
reduced number of CIMP-defining loci occur [27]. We sought to
investigate the methylation profile associated with KRAS mutant
tumors and its association with tumor multiplicity. We found that
KRAS mutant tumors were represented in both multiple and
solitary tumors (33.3% versus 43.4%, respectively; p = 0.7)
(Figure 1). Interestingly, we found that KRAS mutant tumors
showed a distinct methylation profile compared to KRAS wild-type
tumors. We identified 189 CpG sites that showed significant DNA
hypermethylation in KRAS mutant CRCs with respect to KRAS
wild-type tumors (difference in b value $0.1 and p,0.05). Using
more stringent criteria (difference in b value $0,2; p,0.05), we
identified 92 CpG sites significantly hypermethylated. A detailed
list with KRAS-associated hypermethylated CpG sites is shown in
Table S4 and Figure S1. The percentage of CIMP-H did not
differ between KRAS mutant and wild-type tumors (23% versus
35%, respectively; p = 0.7). Similarly, the percentage of CIMP-low
did not differ between KRAS mutant and wild-type tumors (69.2%
versus 55%, respectively; p = 0.485). Overall, although we found
that KRAS mutated tumors display a distinct methylation profiles,
there was association with neither tumor multiplicity nor CIMP
status.
Functional analysis of differential methylation observed
in multiple colorectal cancer
We performed a enrichment analysis on the 102 hypermethy-
lated probes observed in multiple tumors (b value .0,1; p,0.05)
using the Database for Annotation, Visualization and Integrated
Discovery tool in order to find a functional correlation in any
carcinogenic pathway involved in carcinogenesis. This functional
analysis showed the presence and enrichment of genes involved in
different tumorigenic functions: cell motion (12 genes), cell
migration (7 genes), pathways in cancer (8 genes), cell motility (7
genes), regulation of cell proliferation (11 genes), transcription
factor activity (14 genes), and transcription regulation (17 genes)
(Table 3). Full list of functional annotation clustering of
differentially methylated genes is shown in Table S5.
Discussion
In this study we examined for the first time the genome-scale
DNA methylation profile of tumor tissues from patients with
multiple and solitary CRC recruited from a population-based
cohort. We found that tumor multiplicity is associated with a
distinct methylation profile, regardless of age, sex or tumor
location. Compared with solitary tumors, multiple CRCs showed
significant hypermethylation at specific CpG sites and, interest-
ingly, there was a strong association with the CIMP-H described
for CRC. Functional analysis of differentially methylated CpG
sites in multiple tumors showed enrichment of genes involved in
different tumorigenic functions. Results from the methylation
profiling were successfully validated by quantitative PCR assays.
Overall, our data provide new insight into the field cancerization
effect and colorectal carcinogenesis in non-hereditary cases. This
study reveals that somatic hypermethylation plays an important
role in tumor multiplicity and may constitute an interesting
biomarker for CRC risk assessment.
Recent studies have reported a close association between
aberrant DNA methylation and tumor multiplicity
[4,14,16,17,18]. Nosho and colleagues [4] analyzed 47 patients
with synchronous CRC and 2021 solitary tumors for several
methylation markers, including 8 CIMP-specific CpG island (i.e.
CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3,
and SOCS1) and found a significant association between tumor
multiplicity and the presence of CIMP-high (35% in synchronous
tumors versus 8% in solitary tumors; p = 0.036). More important-
Figure 2. Technical validation of Infinium methylation data using Methylight assays. Four genes (MAP1B, HTRA1, ALOX15, TIMP3) were
selected based on strict criteria (b value in solitary tumors ,0.2; b value .0.3 in multiple tumors; difference in b value between multiple versus
solitary $0.2; and an adjusted p value,0.05). Box-plots display the Percentage Methylation Ratio (PMR) determined by Methylight. The lines inside
boxes denote median, and boxes mark the interval between the 25th and 75th percentiles. Black lines denote the highest and lowest PMR value. P
values for the comparison between multiple (red) and solitary (blue) tumors (Mann-Whitney test) are shown.
doi:10.1371/journal.pone.0091033.g002
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ly, the authors found concordant methylation within tumor pairs.
Similarly, Konishi and colleagues [18] analyzed the methylation
status of a limited number of makers in 57 multiple tumors and 69
solitary CRCs, and found that the methylation status of p14 and
MGMT was significantly higher in multiple tumors, showing
concordant methylation for some markers within tumors pairs of
the same colonic site. In line with these observations, we previously
showed that hypermethylation of MGMT and RASSF1A is
independently associated with tumor multiplicity [17]. In another
study, Kamiyama and colleagues [14] analyzed the methylation
status of long interspersed nucleotide element-1 (LINE-1) in
matched cancer tissue and non-cancerous colonic mucosa from
patients with single and multiple right-sided CRCs. The authors
found higher hypomethylation of LINE-1 in both tumor and
normal mucosa from patients with multiple tumors compared to
patients with solitary tumors, and more importantly, LINE-1
hypomethylation was an independent predictor for metachronous
tumors (p = 0.003). The authors suggested that LINE-1 hypo-
methylation in normal mucosa could be used as an epigenetic
predictive biomarker for multiple CRC risk. It is important to note
Figure 3. Heatmap showing the 218 most significantly hypermethylated CpG sites that differentiate CIMP-H (n = 13) and CIMP-0/L
tumors (n = 28) based on the Infinium DNA methylation data. The DNA methylation b-values are represented by using a color scale from red
(high DNA methylation) to green (low DNA methylation). Rows represent probes and columns represent tumor samples. Clinical and molecular
features (group, gender, tumor location, CIMP-H and KRAS mutational status) are represented above the heatmap with horizontal bars.
doi:10.1371/journal.pone.0091033.g003
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that LINE-1 hypomethylation has been previously found to be
inversely correlated with the CIMP phenotype, which may be in
contradiction with our and previous studies. However, the
correlation between LINE-1 hypomethylation and CIMP in
multiple tumors has not been explored in depth, and differences
in patient selection and methodology could explain these
unexpected results. Finally, other studies have hypothesized that
the genetic and epigenetic landscape of a given tumor is
determined by the location in the colon, and that similar
molecular profiles for synchronous tumors is influenced by
proximity [34,35]. Unfortunately, we could not subanalyze this
issue due to the unavailability of the second neoplasm. All these
results suggest that accumulation of aberrant DNA methylation
occurs predominantly in individuals with a propensity to develop
multiple tumors. The results of the present study not only argue in
favor of this hypothesis, but also provide new evidence about the
epigenetic landscape of patients with multiple tumors. The
underlying mechanism of the association between aberrant
methylation and multiplicity is still unknown. Some authors have
suggested an inherited predisposition in some cases [14], with the
accumulation of methylation errors during aging in a genetically
predisposed subgroup of individuals. However, this hypothesis
remains unproven and future studies are needed.
In this study we successfully validated by Methylight the
methylation status of 4 differentially methylated CpG sites
observed in the discovery phase of the study. Specifically, we
observed that MAPB1B, HTRA1, ALOX15, and TIMP3 were
significantly hypermethylated in multiple tumors. MAP1B (Micro-
tubule-Associated Protein 1B) has been previously shown to be
hypermethylated in CIMP-high tumors without MSI, which
mainly correspond to the group of tumors analyzed in our study
[36]. HTRA1 is a member of the HTRA (High-Temperature
Requirement Factor A) family of serine proteases and plays a
Figure 4. Overlap between significantly hypermethylated CpG
sites in multiple and CIMP-H tumors. Blue circle shows 102
hypermethylated CpG sites found in multiple versus solitary tumors and
yellow circle shows the 301 hypermethylated CpG sites in CIMP-H
versus CIMP-L/0 tumors. Remarkably, 76 out of the 102 hypermethy-
lated genes in multiple tumors were also seen to be hypermethylated in
CIMP-H tumors, and are represented as an intersection.
doi:10.1371/journal.pone.0091033.g004
Table 3. Functional annotation clustering of differentially methylated genes found in multiple versus solitary tumors based on
DAVID analysis.
Category Term Count P value Genes
GOTERM_BP_FAT GO:0006928,cell motion 12 1.66821E-05 FGF19, SMO, RET, GDF7,
ARHGEF7, UNC5A, ERBB2,
GBX2, DPYSL5, KITLG,
CXCL12, RUNX3
GOTERM_MF_FAT GO:0003700,transcription factor activity 14 0.000934574 IRX3, THRB, SOX14, SOX5,
ZNF232, SOX8, GLI3,
DLX5, GBX2, HIF3A,
TFAP2A, ALX4, RUNX3,
FOXE3
GOTERM_BP_FAT GO:0016477,cell migration 7 0.002226607 FGF19, SMO, RET,
ARHGEF7, GBX2, KITLG,
CXCL12
KEGG_PATHWAY hsa05200:Pathways in cancer 8 0.002975368 FGF19, SMO, RET, ERBB2,
WNT9B, KITLG, GLI3,
DAPK1
GOTERM_BP_FAT GO:0048870,cell motility 7 0.003771569 FGF19, SMO, RET,
ARHGEF7, GBX2, KITLG,
CXCL12
GOTERM_BP_FAT GO:0042127,regulation of cell proliferation 11 0.004572205 SMO, HRH3, CCKBR,
ERBB2, DLX5, KITLG,
PDGFC, IGFBP3, GLI3,
FOXE3, RUNX3
SP_PIR_KEYWORDS transcription regulation 17 0.009600471 IRX3, MTERF, ZNF264,
THRB, SOX14, SOX5,
ZNF232, PRDM16, SOX8,
GLI3, ZNF681, GBX2,
HIF3A, TFAP2A, ALX4,
RUNX3, FOXE3
doi:10.1371/journal.pone.0091033.t003
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protective role in various malignancies due to its tumor suppressive
properties [37,38,39]. HTRA1 has shown to be silenced through
promoter hypermethylation [38], and proposed as a potential
novel biomarker for diagnosis and prediction in several cancers.
ALOX15 (15-lipoxygenase or 15-LOX) is an inducible and highly
regulated enzyme in normal human cells that plays a key role in
the production of lipid signaling mediators. ALOX15 has recently
shown to be down-regulated in CRC and act as a tumor
suppressor by promoting various anti-tumorigenic events, includ-
ing cell differentiation and apoptosis, and inhibits chronic
inflammation, angiogenesis and metastasis [40]. Finally, Tissue
Inhibitor of Metalloproteinases-3 (TIMP-3) has found to be
silenced in several types of cancer by promoter gene hypermethy-
lation, including CRC [41,42]. Overall, our results show that
multiple tumors are associated with hypermethylation of well-
established tumor suppressor genes.
Independently of the underlying mechanism behind the strong
association between aberrant methylation and tumor multiplicity,
our results suggest that the methylation status of specific markers
could be used to stratify the risk of tumor multiplicity. Kamiyama
and colleagues recently showed that LINE-1 methylation status in
normal colonic mucosa could predict the development of
metachronous CRC with high sensitivity [14], thus representing
a clinically important prognostic biomarker for the identification
of ‘‘high-risk’’ patients. Similarly, the analysis of the methylation
status of specific markers identified in our study could be used in a
clinical scenario to identify high-risk patients and tailor the
surveillance strategy. Prospective studies specifically analyzing this
hypothesis, however, are warranted.
The main strength of this study is that we utilized a population-
based cohort of well-described CRC cases, thus minimizing the
selection bias. Moreover, we used for the first time genome-wide
methylation profiling with Illumina Infinium assay in this setting.
However, we are aware of some limitations. First, we did not
analyze DNA methylation correlation in tumor pairs due to the
design of the EPICOLON II project, in which only one tumor was
collected. Second, CIMP definition was not based on previously
described methylation markers [33]. However, there is currently
no consensus definition of CIMP tumors, and Hinoue and
colleagues [27] recently showed that a new panel based on the
Illumina Infinium DNA methylation platform outperformed the
Methylight-based five-marker panel (i.e. CACNA1G, IGF2, NEU-
ROG1, RUNX3 and SOCS1). The frequency of CIMP-high
frequency in solitary CRCs observed in our study (17%) is in
line with previous figures, which reinforces the accuracy of the new
panel proposed by Hinoue et al. Third, in our study, there were not
BRAF mutant tumors, and accordingly, the association of tumor
multiplicity with a distinct methylation phenotype refers only to
CIMP-high/BRAF wild-type tumors, which can represent up to
40% of CIMP-high tumors. Finally, as our results should be
formally considered not statistically significant when applying
multiple testing corrections, additional studies in other cohorts are
needed in order to confirm the results. However, we were able to
confirm some of the most significant hypermethylated CpG sites
by Methylight, thus reinforcing the validity of our results.
In summary, our results are consistent with the hypothesis that
tumor multiplicity is associated with a distinct pattern of aberrant
methylation. Compared with solitary tumors, multiple CRCs
display more frequently CIMP-H and hypermethylation at other
specific locus. Our results may be important to unravel the
underlying mechanism of tumor multiplicity in the non-hereditary
scenario, and provide novel potential biomarkers for identifying
high-risk patients and tailoring surveillance strategies.
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(TIF)
Table S1 Methylight primers and probes used in this study.
(DOCX)
Table S2 Hypermethylated CpG sites found in multiple versus
solitary tumors based on the Infinium DNA methylation assay.
(PDF)
Table S3 Hypermethylated CpG sites found in CIMP-H versus
CIMP-0/L tumors based on the Infinium DNA methylation assay.
(PDF)
Table S4 Hypermethylated CpG sites found in KRAS mutant
versus. KRAS wild-type tumors based on the Infinium DNA
methylation assay.
(PDF)
Table S5 Functional annotation clustering of differentially
methylated genes found in multiple versus solitary tumors based
on DAVID analysis.
(PDF)
Acknowledgments
The authors thank all study participants of the EPICOLON consortium,
and corresponding staff for their contributions to this project. The
EPICOLON consortium is part of the Gastrointestinal Oncology Group of
the Spanish Gastroenterological Association. Lead author and contact
information: Francesc Balaguer (fprunes@clinic.cat). The members of
the Gastrointestinal Oncology Group of the Spanish Gastroen-
terological Association are: Hospital 12 de Octubre, Madrid: Juan
Diego Morillas (local coordinator), Raquel Mun˜oz, Marisa Manzano,
Francisco Colina, Jose Dı´az, Carolina Ibarrola, Guadalupe Lo´pez, Alberto
Iba´n˜ez; Hospital Clı´nic, Barcelona: Antoni Castells (local coordinator),
Virgı´nia Pin˜ol, Sergi Castellvı´-Bel, Francesc Balaguer, Victoria Gonzalo,
Teresa Ocan˜a, Marı´a Dolores Gira´ldez, Maria Pellise´, Anna Serradesan-
ferm, Leticia Moreira, Miriam Cuatrecasas, Josep M. Pique´; Hospital
Clı´nico Universitario, Zaragoza: A´ngel Lanas (local coordinator), Javier
Alcedo, Javier Ortego; Hospital Cristal-Pin˜or, Complexo Hospitalario
de Ourense: Joaquin Cubiella (local coordinator), Ma Soledad Dı´ez,
Mercedes Salgado, Eloy Sa´nchez, Mariano Vega; Hospital del Mar,
Barcelona: Montserrat Andreu (local coordinator), Anna Abuli, Xavier
Bessa, Mar Iglesias, Agustı´n Seoane, Felipe Bory, Gemma Navarro, Beatriz
Bellosillo, Josep Ma Dedeu, Cristina A´lvarez, Begon˜a Gonzalez; Hospital
San Eloy, Baracaldo and Hospital Donostia, CIBERehd, University
of Country Basque, San Sebastia´n: Luis Bujanda (local coordinator) A´ngel
Cosme, Ine´s Gil, Mikel Larzabal, Carlos Placer, Marı´a del Mar Ramı´rez,
Elisabeth Hijona, Jose M. Enrı´quez-Navascue´s, Jose L. Elosegui; Hospital
General Universitario de Alicante: Artemio Paya´ (EPICOLON I
local coordinator), Rodrigo Jover (EPICOLON II local coordinator),
Cristina Alenda, Laura Sempere, Nuria Acame, Estefanı´a Rojas, Lucı´a
Pe´rez-Carbonell; Hospital General de Granollers: Joaquim Rigau
(local coordinator), A´ngel Serrano, Anna Gime´nez; Hospital General
de Vic: Joan Salo´ (local coordinator), Eduard Batiste-Alentorn, Josefina
Autonell, Ramon Barniol; Hospital General Universitario de
Guadalajara and Fundacio´n para la Formacio´n e Investigacio´n
Sanitarias Murcia: Ana Marı´a Garcı´a (local coordinator), Fernando
Carballo, Antonio Bienvenido, Eduardo Sanz, Fernando Gonza´lez, Jaime
Sa´nchez, Akiko Ono; Hospital General Universitario de Valencia:
Methylation Phenotype of Multiple Sporadic CRC
PLOS ONE | www.plosone.org 10 March 2014 | Volume 9 | Issue 3 | e91033
Mercedes Latorre (local coordinator), Enrique Medina, Jaime Cuquerella,
Pilar Canelles, Miguel Martorell, Jose´ A´ngel Garcı´a, Francisco Quiles,
Elisa Orti; CHUVI-Hospital Meixoeiro, Vigo: EPICOLON I: Juan
Clofent (local coordinator), Jaime Seoane, Antoni Tardı´o, Eugenia
Sanchez; EPICOLON II: Ma Luisa de Castro (local coordinator), Antoni
Tardı´o, Juan Clofent, Vicent Herna´ndez; Hospital Universitari
Germans Trias i Pujol, Badalona and Section of Digestive Diseases
and Nutrition, University of Illinois at Chicago, Chicago, IL: Xavier
Llor (local coordinator), Rosa M. Xicola, Marta Pin˜ol, Merce` Rosinach,
Anna Roca, Elisenda Pons, Jose´ M. Herna´ndez, Miquel A. Gassull;
Hospital Universitari Mu´tua de Terrassa: Fernando Ferna´ndez-
Ban˜ares (local coordinator), Josep M. Viver, Antonio Salas, Jorge Espino´s,
Montserrat Forne´, Maria Esteve; Hospital Universitari Arnau de
Vilanova, Lleida: Josep M. Ren˜e´ (local coordinator), Carmen Pin˜ol, Juan
Buenestado, Joan Vin˜as; Hospital Universitario de Canarias:
Enrique Quintero (local coordinator), David Nicola´s, Adolfo Parra,
Antonio Martı´n; Hospital Universitario La Fe, Valencia: Lidia
Argu¨ello (local coordinator), Vicente Pons, Virginia Pertejo, Teresa Sala;
Hospital Sant Pau, Barcelona: Dolors Gonzalez (local coordinator), Eva
Roman, Teresa Ramon, Maria Poca, Ma Mar Concepcio´n, Marta Martin,
Lourdes Pe´triz; Hospital Xeral Cies, Vigo: Daniel Martinez (local
coordinator); Fundacion Publica Galega de Medicina Xenomica
(FPGMX), CIBERER, Genomic Medicine Group-University of Santiago
de Compostela, Santiago de Compostela, Galicia, Spain: A´ngel Carracedo
(local coordinator), Clara Ruiz-Ponte, Ceres Ferna´ndez-Rozadilla, Ma
Magdalena Castro; Hospital Universitario Central de Asturias:
Sabino Riestra (local coordinator), Luis Rodrigo; Hospital de Galda´cano,
Vizcaya: Javier Ferna´ndez (local coordinator), Jose Luis Cabriada;
Fundacio´n Hospital de Calahorra (La Rioja) La Rioja: Luis Carren˜o
(local coordinator), Susana Oquin˜ena, Federico Bolado; Hospital Royo
Villanova, Zaragoza: Elena Pen˜a (local coordinator), Jose´ Manuel Blas,
Gloria Cen˜a, Juan Jose´ Sebastia´n; Hospital Universitario Reina
Sofı´a, Co´rdoba: Antonio Naranjo (local coordinator).
Author Contributions
Conceived and designed the experiments: VG A. Castells FB. Performed
the experiments: VG VA-E LM JM SC-B XB MA MP RMX XL CR-P A.
Carracedo RJ. Analyzed the data: VG JJL VA-E FB. Wrote the paper: VG
FB A. Carracedo RJ A. Castells SC-B.
References
1. Chen HS, Sheen-Chen SM (2000) Synchronous and ‘‘early’’ metachronous
colorectal adenocarcinoma: analysis of prognosis and current trends. Dis Colon
Rectum 43: 1093–1099.
2. Latournerie M, Jooste V, Cottet V, Lepage C, Faivre J, et al. (2008)
Epidemiology and prognosis of synchronous colorectal cancers. Br J Surg 95:
1528–1533.
3. Pinol V, Andreu M, Castells A, Paya A, Bessa X, et al. (2004) Synchronous
colorectal neoplasms in patients with colorectal cancer: predisposing individual
and familial factors. Dis Colon Rectum 47: 1192–1200.
4. Nosho K, Kure S, Irahara N, Shima K, Baba Y, et al. (2009) A prospective
cohort study shows unique epigenetic, genetic, and prognostic features of
synchronous colorectal cancers. Gastroenterology 137: 1609–1620 e1601–1603.
5. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, et al. (2006)
Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA
methylation analysis. Mod Pathol 19: 1083–1090.
6. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, et al. (2005) MGMT
promoter methylation and field defect in sporadic colorectal cancer. J Natl
Cancer Inst 97: 1330–1338.
7. Young J, Jass JR (2006) The case for a genetic predisposition to serrated
neoplasia in the colorectum: hypothesis and review of the literature. Cancer
Epidemiol Biomarkers Prev 15: 1778–1784.
8. Dykes SL, Qui H, Rothenberger DA, Garcia-Aguilar J (2003) Evidence of a
preferred molecular pathway in patients with synchronous colorectal cancer.
Cancer 98: 48–54.
9. Lawes DA, Pearson T, Sengupta S, Boulos PB (2005) The role of MLH1, MSH2
and MSH6 in the development of multiple colorectal cancers. Br J Cancer 93:
472–477.
10. Pedroni M, Tamassia MG, Percesepe A, Roncucci L, Benatti P, et al. (1999)
Microsatellite instability in multiple colorectal tumors. Int J Cancer 81: 1–5.
11. Balaguer F, Castellvi-Bel S, Castells A, Andreu M, Munoz J, et al. (2007)
Identification of MYH mutation carriers in colorectal cancer: a multicenter,
case-control, population-based study. Clin Gastroenterol Hepatol 5: 379–387.
12. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med
348: 919–932.
13. Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A (2002) Concordant CpG
island methylation in hyperplastic polyposis. Am J Pathol 160: 529–536.
14. Kamiyama H, Suzuki K, Maeda T, Koizumi K, Miyaki Y, et al. (2012) DNA
demethylation in normal colon tissue predicts predisposition to multiple cancers.
Oncogene 31: 5029–5037.
15. Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, et al. (2006) Extensive
DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut
55: 1467–1474.
16. Giovannucci E, Ogino S (2005) DNA methylation, field effects, and colorectal
cancer. J Natl Cancer Inst 97: 1317–1319.
17. Gonzalo V, Lozano JJ, Munoz J, Balaguer F, Pellise M, et al. (2010) Aberrant
gene promoter methylation associated with sporadic multiple colorectal cancer.
PLoS One 5: e8777.
18. Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, et al. (2009) Concordant
DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res
(Phila) 2: 814–822.
19. Gonzalo V, Castellvi-Bel S, Balaguer F, Pellise M, Ocana T, et al. (2008)
[Epigenetics of cancer]. Gastroenterol Hepatol 31: 37–45.
20. Bardhan K, Liu K (2013) Epigenetics and colorectal cancer pathogenesis.
Cancers (Basel) 5: 676–713.
21. Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013) Molecular pathways
involved in colorectal cancer: implications for disease behavior and prevention.
Int J Mol Sci 14: 16365–16385.
22. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, et al. (2003)
Induction of tumors in mice by genomic hypomethylation. Science 300: 489–
492.
23. Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout WM 3rd, et
al. (2005) Global loss of imprinting leads to widespread tumorigenesis in adult
mice. Cancer Cell 8: 275–285.
24. Abuli A, Bessa X, Gonzalez JR, Ruiz-Ponte C, Caceres A, et al. (2010)
Susceptibility genetic variants associated with colorectal cancer risk correlate
with cancer phenotype. Gastroenterology 139: 788–796, 796 e781–786.
25. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, et al. (2009) Genome-
wide DNA methylation profiling using Infinium(R) assay. Epigenomics 1: 177–
200.
26. Gunderson KL (2009) Whole-genome genotyping on bead arrays. Methods Mol
Biol 529: 197–213.
27. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, et al. (2012)
Genome-scale analysis of aberrant DNA methylation in colorectal cancer.
Genome Res 22: 271–282.
28. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, et al. (2000)
MethyLight: a high-throughput assay to measure DNA methylation. Nucleic
Acids Res 28: E32.
29. Perez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Paya A, et al. (2012)
Comparison between universal molecular screening for Lynch syndrome and
revised Bethesda guidelines in a large population-based cohort of patients with
colorectal cancer. Gut 61: 865–872.
30. Goel A, Xicola RM, Nguyen TP, Doyle BJ, Sohn VR, et al. (2010) Aberrant
DNA methylation in hereditary nonpolyposis colorectal cancer without
mismatch repair deficiency. Gastroenterology 138: 1854–1862.
31. Giraldez MD, Balaguer F, Bujanda L, Cuatrecasas M, Munoz J, et al. (2010)
MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal
cancer. Clin Cancer Res 16: 5402–5413.
32. Jiao X, Sherman BT, Huang da W, Stephens R, Baseler MW, et al. (2012)
DAVID-WS: a stateful web service to facilitate gene/protein list analysis.
Bioinformatics 28: 1805–1806.
33. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006)
CpG island methylator phenotype underlies sporadic microsatellite instability
and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:
787–793.
34. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, et al. (2012)
Assessment of colorectal cancer molecular features along bowel subsites
challenges the conception of distinct dichotomy of proximal versus distal
colorectum. Gut 61: 847–854.
35. Zauber P, Huang J, Sabbath-Solitare M, Marotta S (2013) Similarities of
molecular genetic changes in synchronous and metachronous colorectal cancers
are limited and related to the cancers’ proximities to each other. J Mol Diagn 15:
652–660.
36. Ferracin M, Gafa R, Miotto E, Veronese A, Pultrone C, et al. (2008) The
methylator phenotype in microsatellite stable colorectal cancers is characterized
by a distinct gene expression profile. J Pathol 214: 594–602.
37. Mullany SA, Moslemi-Kebria M, Rattan R, Khurana A, Clayton A, et al. (2011)
Expression and functional significance of HtrA1 loss in endometrial cancer. Clin
Cancer Res 17: 427–436.
38. Catalano V, Mellone P, d’Avino A, Shridhar V, Staccioli MP, et al. (2011)
HtrA1, a potential predictor of response to cisplatin-based combination
chemotherapy in gastric cancer. Histopathology 58: 669–678.
39. Lorenzi T, Lorenzi M, Altobelli E, Marzioni D, Mensa E, et al. (2013) HtrA1 in
human urothelial bladder cancer: A secreted protein and a potential novel
biomarker. Int J Cancer.
Methylation Phenotype of Multiple Sporadic CRC
PLOS ONE | www.plosone.org 11 March 2014 | Volume 9 | Issue 3 | e91033
40. Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, et al. (2012) Effects of gut-
targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J Natl
Cancer Inst 104: 709–716.
41. Joensuu EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S, et al.
(2008) Epigenetic signatures of familial cancer are characteristic of tumor type
and family category. Cancer Res 68: 4597–4605.
42. Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, et al. (2006) CpG island
methylation of genes accumulates during the adenoma progression step of the
multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 45:
781–789.
Methylation Phenotype of Multiple Sporadic CRC
PLOS ONE | www.plosone.org 12 March 2014 | Volume 9 | Issue 3 | e91033
